Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1sAs Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.{}

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html